ClinicalTrials.gg
Not yet recruitingNCT07006948Updated Sep 16, 2025

Multicenter Validation Study on Autism Screening Using a Machine-assisted System

An observational study in Autism Spectrum Disorder, Early Developmental Impairment and Language Development Disorders, sponsored by Children's Hospital of Fudan University. Not yet recruiting at 10 sites in China. Open to participants aged 18 Months to 30 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Children's Hospital of Fudan University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,000
Ages
18 Months to 30 Months
Sex
All
01

Study summary

The goal of this observational study is to assess the effectiveness of a machine-assisted system for early screening of autism. The main questions it aims to answer are:

  • Does the machine-assisted system including 5 main behavioral paradigms identify toddlers with autism from those with other neurodevelopmental disorders and typical development?
  • Are there any differences in the early symptoms of autism among toddlers over the whole mainland China? Participants will receive some developmental and social communicational evaluations for clinical diagnoses. They will also receive the behavior evaluations of the machine-assisted system. The above evaluations will be performed just once.
Read the detailed description

The current study is a diagnostic accuracy study. In total, 1000 Toddlers with autism spectrum disorder, global developmental delay, language disorder, and typical development (n=250 for each group) will be recruited in this study. The gold standard of the diagnosis of autism spectrum disorder will be the clinical diagnosis from developmental and behavioral pediatricians, and the diagnoses will be confirmed by Autism Diagnostic Observation Schedule-2nd edition and Griffiths Development Scales-Chinese edition(GDS-C). The diagnostic accuracy of the machine-assisted system for early screening of autism will be evaluated.

02

Conditions studied

  • Autism Spectrum Disorder
  • Early Developmental Impairment
  • Language Development Disorders
03

In context

Autism Spectrum Disorder

1,724 studies on the registry are indexed under Autism Spectrum Disorder; 500 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 102 across 320 observational studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 95 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months to 30 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The diagnostic accuracy study will be performed in children with ASD, GDD, LD, and healthy, typically developing children aged between 1.5 to 2.5 years old.

Eligibility criteria

ASD group:

Inclusion Criteria:

  1. Children diagnosed with ASD according to a clinical judgement based on the criteria of ASD in and further confirmed with ADOS-2;
  2. Ages 1.5-2.5 years;
  3. Parents/caregivers understand the content of the study and agree to participate in.

GDD group:

Inclusion Criteria:

  1. Age 1.5-2.5 years, gestational age 37-42 weeks, birth weight 2500-4000g;
  2. Clinically diagnosed with GDD (Global Developmental Delay) according to the DSM-V diagnostic criteria, with a Griffiths Development Scales-Chinese edition(GDS-C) assessment showing a Developmental Quotient (DQ) ≤75 in two or more domains;
  3. Those who did not meet the initial screening positivity criteria for ASD (Autism Spectrum Disorder) using M-CHAT-R/F.

LD group:

Inclusion Criteria:

  1. Age 1.5-2.5 years, gestational age 37-42 weeks, birth weight 2500-4000 g;
  2. Clinically diagnosed with LD (Language Disorder) according to the DSM-V diagnostic criteria, with a Developmental Quotient (DQ) ≤75 in the language domain of the Griffiths Development Scales-Chinese edition(GDS-C) and DQ >75 in all other domains;
  3. Those who did not meet the initial screening positivity criteria for ASD (Autism Spectrum Disorder) assessed by M-CHAT-R/F

Exclusion Criteria for ASD, GDD, and LD groups:

  1. Rett Syndrome, Fragile X Syndrome, Angelman Syndrome, Prader-Willi Syndrome, tuberous sclerosis, and other syndromes caused by known genetic defects or inherited metabolic diseases;
  2. Children with brain injuries, specific chronic or congenital diseases.
  3. The gestational age is less than 37 weeks, or the birth weight is lower than 2500g.

TD group:

Inclusion Criteria:

  1. Healthy, typically developing toddlers aged 1.5-2.5 years ;
  2. gestational age of 37-42 weeks, birth weight of 2500-4000 g;
  3. Developmental Quotients(DQs) are greater than 75 in all domains of theGriffiths Development Scales-Chinese edition(GDS-C);
  4. Screened negative by M-CHAT-R/F screening for autism spectrum disorder (ASD).

Exclusion Criteria:

Children with neurodevelopmental disorders (e.g., developmental delay, language impairment), neurological conditions (e.g., epilepsy, tuberous sclerosis), or other severe chronic diseases were excluded.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • ASD group

    This group includes toddlers diagnosed with autism spectrum disorder aged between 1.5 to 2.5 years old.

    Diagnostic Test: Autism Diagnostic Observation Schedule, the 2nd edition(ADOS-2) · Diagnostic Test: Griffiths Developmental Scales, Chinese edition(GDS-C)

  • GDD group

    This group includes toddlers diagnosed with global development disorder aged between 1.5 to 2.5 years old.

    Diagnostic Test: Griffiths Developmental Scales, Chinese edition(GDS-C)

  • LD group

    This group includes toddlers diagnosed with language disorder aged between 1.5 to 2.5 years old.

    Diagnostic Test: Griffiths Developmental Scales, Chinese edition(GDS-C)

  • TD group

    This group includes typically developing toddlers aged between 1.5 to 2.5 years old.

    Diagnostic Test: Griffiths Developmental Scales, Chinese edition(GDS-C)

Interventions

  • Diagnostic testAutism Diagnostic Observation Schedule, the 2nd edition(ADOS-2)

    The toddlers diagnosed with ASD will receive the ADOS-2 evaluation to confirm the diagnosis.

  • Diagnostic testGriffiths Developmental Scales, Chinese edition(GDS-C)

    The toddlers diagnosed with ASD, GDD, LD, and typically developing will receive the GDS-C evaluation to confirm the diagnosis.

06

What researchers measure

Primary outcomes

  1. Total Score of 5 main social behaviors

    The 5 main social behaviors include Response to name, Response to instructions, Joint attention, request by pointing, and free play. Scores of the 5 scenes range from 0 to 4, and the total score ranges from 0 to 16. Higher score indicates better social skills. Subjects' behaviors will be scored both by investigators and the machine-assisted system.

    Time frame: The assessment will be performed during 1.5 to 2.5 years old.

  2. Clinical diagnoses

    The clinical diagnoses of autism spectrum disorder (ASD), global developmental delay (GDD), and language disorder (LD) will be made according to the standard of DSM-5. The diagnosis of ASD will be confirmed by The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F) and Autism Diagnostic Observation Schedule, the 2nd edition (ADOS-2). The diagnoses of GDD and LD will be confirmed by Griffiths Development Scales-Chinese edition (GDS-C). Subjects in TD group will also receive assessments of M-CHAT-R/F, (negative) and GDS-C (DQs\>75).

    Time frame: The diagnoses will be made during 1.5 to 2.5 years old.

  3. Scores of Autism Diagnostic Observation Schedule-2nd edition(ADOS-2)

    The scores of social affect and restricted repetitive behaviors and the comparison score of ADOS-2 will be used for confirming the clinical diagnosis of autism spectrum disorder(ASD). The minimum and maximum scores of ADOS-2 are 0 and 28, and the comparison score of ADOS-2 ranges from 1 to 10, in which higher scores mean a worse outcome.

    Time frame: The assessment will be performed during 1.5 to 2.5 years old.

  4. development quotient development quotient Development quotients (DQs) of Griffiths Developmental Scales-Chinese edition(GDS-C)

    DQs of Griffiths Development Scales-Chinese edition(GDS-C) will be used for confirming the diagnoses of global developmental delay(GDD) and language disorder(LD), also be used to evaluate the development level of typically developing toddlers. The average scores of DQ in different domains are 100, and the standard deviations are 15. The DQ lower than 70(including 70) means lower than normal.

    Time frame: The assessment will be performed during 1.5 to 2.5 years old.

07

Study locations

10 sites
  • Hefei First People's Hospital
    Hefei, Anhui 230061, China
    • Peiting Shen · Contact
  • Xiamen Children's Hospital
    Xiamen, Fujian 361004, China
    • Huiping Li · Contact
  • Liuzhou Maternity and child Healthcare Hospital
    Liuzhou, Guangxi 545001, China
    • Aiwen Li · Contact
  • The Sixth Affiliated Hospital of Harbin Medical University
    Harbin, Helongjiang 150023, China
    • Lijie Wu · Contact
  • Kunshan Maternal and Child Health Care Hospital
    Kunshan, Jiangsu 215300, China
    • Qinyi Zhang · Contact15950187911
  • Xi'an Children's Hospital
    Xi'an, Shaanxi 710082, China
    • Chunyang Li · Contact
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality 201102, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan 610073, China
    • Lan Zhang · Contact
  • Dehong People's Hospital
    Dehong, Yunnan 678499, China
    • Xueyan Li · Contact
  • Ningbo Women and Children's Hospital
    Ningbo, Zhejiang 315012, China
    • Lanqiu Lv · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jun 2028, 33 months later.

Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 33 months is below that.

Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 5, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Jun 15, 2028
CompletionEst.
Jun 15, 2029
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07006948
Collaborators
Harbin Institute of Technology, Shenzhen, Kunshan City Maternal and Child Health, Hefei First People's Hospital, Ningbo Women & Children's Hospital, Xiamen Children's Hospital, Chengdu Women's and Children's Central Hospital, Liuzhou Maternity and Child Healthcare Hospital, Xian Children's Hospital, Dehong People's Hospital, The Sixth Affiliated Hospital of Harbin Medical University
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Jun 15, 2028 (estimated)
Completion
Jun 15, 2029 (estimated)
Last update
Sep 16, 2025

Study contacts

Bingrui Zhou
Contact
zbr1800@163.com
13701989113
Xiu Xu
principal investigator · Children's Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion